Current status of lipid management of hypertensive patients

Hypertension Research

Volumn 26, Issue 9, 2003, Pages 699-704

  Matsubara, Koichi ^a   Yamamoto, Yasutaka ^a   Sonoyama, Kazuhiko ^a   Igawa, Go ^a   Furuse, Masako ^a   Yatsuhashi, Toru ^a   Hamada, Toshihiro ^a   Ogino, Kazuhide ^a   Igawa, Osamu ^a   Hisatome, Ichiro ^a   Shigemasa, Chiaki ^a  

^a TOTTORI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hyperlipidemia; Hypertension; Lipid lowering therapy

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; AGE DISTRIBUTION; AGED; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HEALTH CARE QUALITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 12444320408     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.699     Document Type: Review

References (32)

1. Japanese Society of Hypertension Guidelines Subcommittee for the Management Hypertension: Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613-634.
2. Kannel WB, Castelli WP, Gordon T: Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Study. Ann Intern Med 1979; 90: 85-91.
3. Wong ND, Wilson PW, Kannel WB: Serum cholesterol as prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med 1991; 115: 687-693.
4. The MRFIT Research Group: Mortality rates after 10.5 years for participants in the multiple risk factor intervention trial: findings related to a priori hypotheses of the trial. JAMA 1990; 263: 1795-1801.
5. West of Scotland Coronary Prevention Study Group: Influence of pravastatin and plasma lipid on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1995; 97: 1440-1445.
6. Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-1622.
7. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
8. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
9. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group: Prevention of cardiovascular events and death with pravastatin in patient with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
10. Pitt B, Waters D, Brown WV, et al: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease: atorvastatin versus revascularization treatment investigators. N Engl J Med 1999; 341: 70-76.
11. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: the Expert Panel. Arch Intern Med 1988; 148: 36-69.
12. National Cholesterol Education Program Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-1445.
13. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D: Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-1331.
14. Hata Y, Mabuchi H, Saito Y, et al: Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults. J Atheroscler Thromb 2002; 9: 1-27.
15. The Kyushu Lipid Intervention Study Group: Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. J Atheroscler Thromb 2000; 7: 110-121.
16. Ito H, Ouchi Y, Ohashi Y, et al: A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE). J Atheroscler Thromb 2001; 8: 33-44.
17. Itakura H: J-LIT (Japan Lipid Intervention Trial). Nippon Rinsho 2001; 59 (Suppl 3): 462-468.
18. Yamamoto Y, Sonoyama K, Matsubara K, et al: The status of hypertension management in Japan in 2000. Hypertens Res 2002; 25: 717-725.
19. Borghi C: Interaction between hypercholesterolemia and hypertension: implications for therapy. Curr Opin Nephrol Hypertens 2002; 11: 489-496.
20. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E: Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35: 549-555.
21. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-250.
22. Egashira K, Ni W, Inoue S, et al: Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions. Hypertens Res 2000; 23: 353-358.
23. Chen H, Ikeda U, Shimpo M, Shimada K: Direct effects of statins on cells primarily involved in atherosclerosis. Hypertens Res 2000; 23: 187-192.
24. Egashira K, Hirooka Y, Kai H, et al: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hyperchoresterolemia. Circulation 1994; 89: 2519-2524.
25. Isles CG, Paterson JR: Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. QJM 2000; 93: 567-574.
26. Yee HS, Fong NT: Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann Pharmacother 1998; 32: 1030-1043.
27. Chong BH, Seeger JD, Franklin C: Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001; 111: 390-400.
28. Staels B, Auwerx J: Regulation of apo A-I gene expression by fibrates. Atherosclerosis 1998; 137: S19-S23.
29. Jorge Y, Carmen FB, Robert JG, Frederick S, Darleen L, Joel MG: A community-wide survey of physician practices and attitudes toward cholesterol management in patients with recent acute myocardial infarction. Arch Intern Med 2002; 162: 797-804.
30. Roger RW, Steven CH, Gerardo H, et al: Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol 2001; 87: 129-135.
31. Carmine G, Paola B, Adriana G, et al: Lipoprotein(a) plasma concentrations, apolipoprotein(a) polymorphism and family history of coronary heart disease in patients with essential hypertension. J Cardiovasc Risk 1996; 3: 191-197.
32. Colditz GA, Rimm EB, Giovannucci E, et al: A prospective study of parental history of myocardial infarction and coronary artery disease in men. Am J Cardiol 1991; 67: 933-938.